December 22, 2020 by Chain Drug Review
COVID-19, Dr. Reddy’s, Reeqonus
Leading Headlines, Pharmacy
MISSISSAUGA, Ontario — Dr. Reddy’s has filed an application for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Reeqonus is also known as Avigan, which was developed by Fujifilm Toyama Chemical
October 5, 2020 by Chain Drug Review
Dr. Reddy’s, ValGenesis
Pharmacy, Supplier News
SAN FRANCISCO — ValGenesis, a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), announced on Monday that it has digitized the validation process at Dr. Reddy’s Laboratories across multiple sites, driven by ValGenesis VLMS – the industry’s most trusted electronic validation lifecycle management system. Dr. Reddy’s Laboratories is a global integrated pharmaceutical company operating
March 18, 2020 by Chain Drug Review
Dr. Reddy’s, Marc Kikuchi, ziprasidone mesylate for injection
Pharmacy, Supplier News
PRINCETON, N.J. — Dr. Reddy’s has launched ziprasidone mesylate for injection, 20 mg (base)/mL single-dose vials, the therapeutic generic equivalent of Geodon (ziprasidone mesylate) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration. “We’re pleased to bring the first generic of ziprasidone mesylate for injection to market for patients who will benefit from
February 10, 2020 by Chain Drug Review
Dr. Reddy’s, Marc Kikuchi, Syprine, trientine hydrochloride capsules
Pharmacy, Supplier News
PRINCETON, N.J. — Dr. Reddy’s announced the launch of trientine hydrochloride capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules, approved by the U.S. Food and Drug Administration. “We are pleased to provide this convenient alternative for patients, pharmacists and distribution partners,” explains Marc Kikuchi, chief executive officer and head
September 16, 2019 by Chain Drug Review
Dr. Reddy’s, Dr. Reddy’s O-T-C lansoprazole delayed-release capsules USP, Milan Kalawadia, Prevacid 24HR capsules
Pharmacy, Supplier News
PRINCETON, N.J. — Dr. Reddy’s announced Monday the launch of lansoprazole delayed-release capsules USP, 15 mg, an over-the-counter (O-T-C) store-brand equivalent of Prevacid 24HR capsules, in the United States market, as approved by the U.S. Food and Drug Administration. Dr. Reddy’s O-T-C lansoprazole delayed-release capsules USP, 15 mg, is an over-the-counter, Proton Pump Inhibitor (PPI)
July 22, 2019 by Chain Drug Review
Alembic, Alkem, Amneal Pharmaceuticals, Dr. Reddy’s, generic version of Lyrica, InvaGen, MSN Laboratories, pregabalin capsules, Rising Pharmaceuticals, Rob Stewart, Sciegen, Teva
Pharmacy, Supplier News
BRIDGEWATER, N.J. — The Food and Drug Administration has approved a number of applications for the generic version of Pfizer’s Lyrica (pregabalin). The FDA gave the green light to the following companies: Amneal, Alembic, Alkem, Dr. Reddy’s, InvaGen, MSN Laboratories, Rising Pharmaceuticals, Sciegen, and Teva. Amneal’s generic version of Lyrica (pregabalin capsules) will be available
July 19, 2019 by Chain Drug Review
Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets, Dr. Reddy’s, Milan Kalawadia
Pharmacy, Supplier News
PRINCETON, N.J. — Dr. Reddy’s Laboratories has introduced an over-the-counter store-brand equivalent of Chattem’s Allegra-D (fexofenadine 60 mg and pseudoephedrine 120 mg) extended-release tablets. This is an O-T-C store-brand equivalent of Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets, in the United States market, as approved by the U.S. Food and Drug Administration (USFDA). “We
July 10, 2019 by Chain Drug Review
and guaifenesin 1200 mg and pseudoephedrine HCl 120 mg, Dr. Reddy’s, guaifenesin 600 mg and pseudoephedrine HCl 60 mg, Mucinex D Extended Release Tablet
Pharmacy, Supplier News
PRINCETON, N.J. — Dr. Reddy’s announced launch of an over-the-counter (O-T-C) store-brand equivalent of Mucinex D Extended Release Tablets in two strengths— guaifenesin 600 mg and pseudoephedrine HCl 60 mg, and guaifenesin 1200 mg and pseudoephedrine HCl 120 mg—in the United States market, as approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy’s
February 21, 2019 by Chain Drug Review
buprenorphine and naloxone sublingual Film, Dr. Reddy’s, Marc Kikuchi, Suboxone (buprenorphine and naloxone) sublingual film
Pharmacy, Supplier News
PRINCETON, N.J.— Dr. Reddy’s Laboratories announced this week the re-launch of its buprenorphine and naloxone sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone (buprenorphine and naloxone) sublingual film, in the U.S. market. The re-launch comes on the heels of a favorable
February 1, 2019 by Chain Drug Review
Dr. Reddy’s, Marc Kikuchi
Supplier News
PRINCETON, N.J. — Marc Kikuchi has been named chief executive officer of North American generics at Dr. Reddy’s Laboratories Ltd. “Dr. Reddy’s is a great company with a wide portfolio and remarkable heritage,” says Kikuchi. “I am excited to join Dr. Reddy’s and look forward to leveraging my past experiences to steer the company’s new
June 13, 2016 by Chain Drug Review
Allergan, Allergan’s generics business, Alok Sonig, Dr. Reddy’s, Ducere Pharma, G.V. Prasad, Teva
Pharmacy, Supplier News
HYDERABAD, India, and PRINCETON, N.J. — Dr. Reddy’s Laboratories plans to buy eight Abbreviated New Drug Applications (ANDAs) in the United States from Teva Pharmaceutical Industries Ltd. and an affiliate of Allergan plc for $350 million in cash. Dr. Reddy’s, which announced the agreement over the weekend, said the acquired products are being divested by